mazindol has been researched along with Weight Loss in 9 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 9.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients." | 8.95 | Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. ( Correr, CJ; Fernandez-Llimos, F; Lucchetta, RC; Otuki, MF; Pontarolo, R; Radominski, RB; Riveros, BS, 2017) |
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 5.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "Mazindol was given orally, 1." | 5.29 | Effects of mazindol in two patients with Prader-Willi syndrome. ( Itoh, M; Koeda, T; Ohno, K; Takeshita, K, 1995) |
| "To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss." | 5.19 | A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. ( Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H, 2014) |
| " The two phenylpropanolamine studies gave the same weight losses, but the dropouts were 37% at 8 weeks for free care vs." | 5.09 | Methods to maximize retention in weight loss studies. ( Bray, GA; Greenway, FL; Marlin, RL, 1999) |
| "The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients." | 4.95 | Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. ( Correr, CJ; Fernandez-Llimos, F; Lucchetta, RC; Otuki, MF; Pontarolo, R; Radominski, RB; Riveros, BS, 2017) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Mazindol was given orally, 1." | 1.29 | Effects of mazindol in two patients with Prader-Willi syndrome. ( Itoh, M; Koeda, T; Ohno, K; Takeshita, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Arguelles-Tello, FA | 1 |
| Kammar-García, A | 1 |
| Trejo-Jasso, CA | 1 |
| Huerta-Cruz, JC | 1 |
| Barranco-Garduño, LM | 1 |
| Rocha-González, HI | 1 |
| Reyes-García, JG | 1 |
| Lucchetta, RC | 1 |
| Riveros, BS | 1 |
| Pontarolo, R | 1 |
| Radominski, RB | 1 |
| Otuki, MF | 1 |
| Fernandez-Llimos, F | 1 |
| Correr, CJ | 1 |
| Suplicy, H | 1 |
| Boguszewski, CL | 1 |
| dos Santos, CM | 1 |
| do Desterro de Figueiredo, M | 1 |
| Cunha, DR | 1 |
| Radominski, R | 1 |
| Mancini, MC | 1 |
| Halpern, A | 1 |
| Itoh, M | 1 |
| Koeda, T | 1 |
| Ohno, K | 1 |
| Takeshita, K | 1 |
| Ryan, DH | 2 |
| Bray, GA | 3 |
| Helmcke, F | 1 |
| Sander, G | 1 |
| Volaufova, J | 1 |
| Greenway, F | 1 |
| Subramaniam, P | 1 |
| Glancy, DL | 1 |
| Greenway, FL | 2 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Marlin, RL | 1 |
| Murphy, JE | 1 |
| Donald, JF | 1 |
| Molla, AL | 1 |
| Crowder, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to failure to enroll) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mazindol and Weight Loss
| Article | Year |
|---|---|
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
Topics: Appetite Depressants; Diethylpropion; Humans; Mazindol; Obesity; Overweight; Publication Bias; Repro | 2017 |
Pharmacological treatment of obesity.
Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Ene | 2006 |
4 trials available for mazindol and Weight Loss
| Article | Year |
|---|---|
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglyc | 2022 |
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Die | 2014 |
Methods to maximize retention in weight loss studies.
Topics: Appetite Depressants; Double-Blind Method; Humans; Mazindol; Patient Dropouts; Patient Selection; Ph | 1999 |
A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.
Topics: Adult; Diethylpropion; Female; Humans; Male; Mazindol; Middle Aged; Obesity; Weight Loss | 1975 |
3 other studies available for mazindol and Weight Loss
| Article | Year |
|---|---|
Effects of mazindol in two patients with Prader-Willi syndrome.
Topics: Adolescent; Appetite Depressants; Central Nervous System Stimulants; Child; Humans; Male; Mazindol; | 1995 |
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Counseling; Dexfenfluramine; Drug | 1999 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |